<DOC>
	<DOCNO>NCT02891148</DOCNO>
	<brief_summary>To investigate safety , tolerability , pharmacokinetics pharmacodynamics follow single rise dos BI 690517</brief_summary>
	<brief_title>Single Rising Dose Study BI 690517 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead electrocardiogram , clinical laboratory test Age 18 50 year ( incl . ) BMI 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Exclusion criterion : Any find medical examination ( include blood pressure ( BP ) , pulse rate ( PR ) electrocardiogram ( ECG ) ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 100 140 mmHg , diastolic blood pressure outside range 60 90 mmHg , pulse rate outside range 50 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Use drug within 30 day prior administration trial medication might reasonably influence result trial ( incl . QT/QTc interval prolongation ) Participation another trial investigational drug administer within 60 day prior plan administration trial medication , current participation another trial involve administration investigational drug Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke specify trial day Alcohol abuse ( consumption 30 g per day male ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( QTc interval repeatedly great 450 m male ) relevant ECG find screen A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study Values serum sodium potassium outside normal range screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>